NF Bot
@nfbot.bsky.social
NF Bot looking to publish any news, pubmed articles, NF Events, Reddit posts and Bluesky posts.
Please let me know if something doesn't look right.
Please let me know if something doesn't look right.
"Aperitif with the author": Valentina Mastroianni presents the book "It was all life" - Canove, Saturday 6 December 2025 - Asiago.it
"Aperitif with the author": Valentina Mastroianni presents the book "It was all life" - Canove, Saturday 6 December 2025 - Asiago.it
"Aperitif with the author": Valentina Mastroianni presents the book "It was all life" - Canove, Saturday 6 December 2025 - Asiago.it
news.google.com
December 10, 2025 at 5:56 PM
"Aperitif with the author": Valentina Mastroianni presents the book "It was all life" - Canove, Saturday 6 December 2025 - Asiago.it
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com UK
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com UK
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com UK
news.google.com
December 10, 2025 at 5:56 PM
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com UK
Community provides support for educator encountering health battles - Winchester Sun
Community provides support for educator encountering health battles - Winchester Sun
Community provides support for educator encountering health battles - Winchester Sun
news.google.com
December 10, 2025 at 5:56 PM
Community provides support for educator encountering health battles - Winchester Sun
Neurofibromatosis Type 1 (NF1) Market representing a strong CAGR of 10%-13% during the forecast period. - openPR.com
Neurofibromatosis Type 1 (NF1) Market representing a strong CAGR of 10%-13% during the forecast period. - openPR.com
Neurofibromatosis Type 1 (NF1) Market representing a strong CAGR of 10%-13% during the forecast period. - openPR.com
news.google.com
December 10, 2025 at 5:56 PM
Neurofibromatosis Type 1 (NF1) Market representing a strong CAGR of 10%-13% during the forecast period. - openPR.com
FDA Approves Imfinzi for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma - Clinical Oncology News
FDA Approves Imfinzi for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma - Clinical Oncology News
FDA Approves Imfinzi for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma - Clinical Oncology News
news.google.com
December 10, 2025 at 5:56 PM
FDA Approves Imfinzi for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma - Clinical Oncology News
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
news.google.com
December 10, 2025 at 5:56 PM
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
Pulmonary Hypertension in Rare Disease Overlap: Neurofibromatosis Type 1 Meets Sarcoidosis - Cureus
Pulmonary Hypertension in Rare Disease Overlap: Neurofibromatosis Type 1 Meets Sarcoidosis - Cureus
Pulmonary Hypertension in Rare Disease Overlap: Neurofibromatosis Type 1 Meets Sarcoidosis - Cureus
news.google.com
December 10, 2025 at 5:56 PM
Pulmonary Hypertension in Rare Disease Overlap: Neurofibromatosis Type 1 Meets Sarcoidosis - Cureus
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
news.google.com
December 10, 2025 at 4:56 PM
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
Neurofibromatosis Type 1 (NF1) Market representing a strong CAGR of 10%-13% during the forecast period. - openPR.com
Neurofibromatosis Type 1 (NF1) Market representing a strong CAGR of 10%-13% during the forecast period. - openPR.com
Neurofibromatosis Type 1 (NF1) Market representing a strong CAGR of 10%-13% during the forecast period. - openPR.com
news.google.com
December 10, 2025 at 4:56 PM
Neurofibromatosis Type 1 (NF1) Market representing a strong CAGR of 10%-13% during the forecast period. - openPR.com
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
news.google.com
December 10, 2025 at 4:56 PM
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
Koselugo Approved for Adults with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas - Clinical Oncology News
Koselugo Approved for Adults with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas - Clinical Oncology News
Koselugo Approved for Adults with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas - Clinical Oncology News
news.google.com
December 10, 2025 at 4:56 PM
Koselugo Approved for Adults with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas - Clinical Oncology News
Pulmonary Hypertension in Rare Disease Overlap: Neurofibromatosis Type 1 Meets Sarcoidosis - Cureus
Pulmonary Hypertension in Rare Disease Overlap: Neurofibromatosis Type 1 Meets Sarcoidosis - Cureus
Pulmonary Hypertension in Rare Disease Overlap: Neurofibromatosis Type 1 Meets Sarcoidosis - Cureus
news.google.com
December 10, 2025 at 4:56 PM
Pulmonary Hypertension in Rare Disease Overlap: Neurofibromatosis Type 1 Meets Sarcoidosis - Cureus
FDA Approves Imfinzi for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma - Clinical Oncology News
FDA Approves Imfinzi for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma - Clinical Oncology News
FDA Approves Imfinzi for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma - Clinical Oncology News
news.google.com
December 10, 2025 at 3:56 PM
FDA Approves Imfinzi for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma - Clinical Oncology News
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
news.google.com
December 10, 2025 at 3:56 PM
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
FDA Approves Keytruda With Padcev for Muscle-Invasive Bladder Cancer - Clinical Oncology News
FDA Approves Keytruda With Padcev for Muscle-Invasive Bladder Cancer - Clinical Oncology News
FDA Approves Keytruda With Padcev for Muscle-Invasive Bladder Cancer - Clinical Oncology News
news.google.com
December 10, 2025 at 3:56 PM
FDA Approves Keytruda With Padcev for Muscle-Invasive Bladder Cancer - Clinical Oncology News
Community provides support for educator encountering health battles - Winchester Sun
Community provides support for educator encountering health battles - Winchester Sun
Community provides support for educator encountering health battles - Winchester Sun
news.google.com
December 10, 2025 at 3:56 PM
Community provides support for educator encountering health battles - Winchester Sun
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
news.google.com
December 10, 2025 at 3:56 PM
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
Koselugo Approved for Adults with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas - Clinical Oncology News
Koselugo Approved for Adults with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas - Clinical Oncology News
Koselugo Approved for Adults with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas - Clinical Oncology News
news.google.com
December 10, 2025 at 3:56 PM
Koselugo Approved for Adults with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas - Clinical Oncology News
Pulmonary Hypertension in Rare Disease Overlap: Neurofibromatosis Type 1 Meets Sarcoidosis - Cureus
Pulmonary Hypertension in Rare Disease Overlap: Neurofibromatosis Type 1 Meets Sarcoidosis - Cureus
Pulmonary Hypertension in Rare Disease Overlap: Neurofibromatosis Type 1 Meets Sarcoidosis - Cureus
news.google.com
December 10, 2025 at 3:56 PM
Pulmonary Hypertension in Rare Disease Overlap: Neurofibromatosis Type 1 Meets Sarcoidosis - Cureus
FDA Approves Imfinzi for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma - Clinical Oncology News
FDA Approves Imfinzi for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma - Clinical Oncology News
FDA Approves Imfinzi for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma - Clinical Oncology News
news.google.com
December 10, 2025 at 2:56 PM
FDA Approves Imfinzi for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma - Clinical Oncology News
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
news.google.com
December 10, 2025 at 2:56 PM
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
FDA Approves Keytruda With Padcev for Muscle-Invasive Bladder Cancer - Clinical Oncology News
FDA Approves Keytruda With Padcev for Muscle-Invasive Bladder Cancer - Clinical Oncology News
FDA Approves Keytruda With Padcev for Muscle-Invasive Bladder Cancer - Clinical Oncology News
news.google.com
December 10, 2025 at 2:56 PM
FDA Approves Keytruda With Padcev for Muscle-Invasive Bladder Cancer - Clinical Oncology News
Community provides support for educator encountering health battles - Winchester Sun
Community provides support for educator encountering health battles - Winchester Sun
Community provides support for educator encountering health battles - Winchester Sun
news.google.com
December 10, 2025 at 2:56 PM
Community provides support for educator encountering health battles - Winchester Sun
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
news.google.com
December 10, 2025 at 2:56 PM
Neurofibromatosis Type 2 (NF2) Market is projected to reach USD 654 million by 2034 - openPR.com
Koselugo Approved for Adults with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas - Clinical Oncology News
Koselugo Approved for Adults with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas - Clinical Oncology News
Koselugo Approved for Adults with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas - Clinical Oncology News
news.google.com
December 10, 2025 at 2:56 PM
Koselugo Approved for Adults with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas - Clinical Oncology News